Forendo plans phase 1b study of endometriosis treatment inhibitor in summer

Forendo Pharma has completed Phase 1a study of FOR-6219, an HSD17B1 inhibitor for the treatment of endometriosis, with single and multiple ascending oral doses of FOR-6219 in 36 healthy postmenopausal women, it said Thursday.

The company said the pharmacokinetic results showed a dose proportionate exposure and no significant food effect.   

Phase 1b study is planned to be initiated in the summer this year.

Risto Lammintausta, CEO of Forendo Pharma, said: “We are encouraged by the positive results of this first clinical study. It is an important milestone to Forendo. This data gives a good basis to progress the development of FOR-6219 towards a truly differentiated, next generation treatment  for endometriosis patients.”